天贝止喘汤对支气管哮喘小鼠Th1/Th2影响的研究

目的观察天贝止喘汤对支气管哮喘小鼠肺组织、血清Ig E、支气管肺泡灌洗液IL-4、IL-10、IL-12和TNF-α影响,研究天贝止喘汤保护哮喘小鼠可能的机制。方法 70只健康SPF级雌性BALB/c小鼠适应性饲养后,分为7组(空白对照组、哮喘模型组、天贝止喘汤低剂量组、天贝止喘汤中剂量组、天贝止喘汤高剂量组、小青龙组、地塞米松组),10只/组。卵清白蛋白建立小鼠支气管哮喘气道炎症模型,取材后观察肺组织变化、测定血清Ig E、支气管肺泡灌洗液IL-4、IL-10、IL-12和TNF-α水平变化。结果空白组肺组织无明显炎症细胞浸润、肺组织及气道壁形态结构完整;模型组肺组织有大量炎症细胞浸润、肺组织及气道壁增厚明显,结构受损,其余各药物治疗组较模型组均有不同程度改善。与空白组相比,模型组和各药物治疗组血清Ig E水平、支气管肺泡灌洗液IL-4、TNF-α水平显著升高(P<0.05),IL-10、IL-12水平显著降低(P<0.05);与模型组相比,各药物治疗组血清Ig E水平、支气管肺泡灌洗液IL-4、TNF-α水平显著降低(P<0.05),IL-10、IL-12水平显著升高(P<0.05)。结论天贝止喘汤可能通过调节Th1/Th2平衡,调节炎性细胞因子水平保护哮喘小鼠,高剂量效果更明显。     

支气管哮喘小鼠气道中IL-17表达与气道重塑关系的相关研究

目的研究气道中IL-17表达对支气管哮喘小鼠气道重塑的相关关系。方法选80只BALB/c小鼠依据随机分组原则分成四组,分别是对照组、OVA致敏哮喘+IL-17抗体组、单纯OVA致敏哮喘组和OVA致敏哮喘+IL-17组,每组20只。用卵蛋白致敏,气道激发8周,激发结束后比较四组肺泡灌洗液IL-17水平、气道组织病理改变和肺组织免疫化学染色。结果四组小鼠肺泡灌洗液中IL-17水平依次增高,且任意两组之间有显著性差异;在IL-17水平增高的情况下,气道组织病理越严重,气道组织中TGF-β1蛋白逐渐增加。结论 IL-17的表达能够促进支气管哮喘小鼠的气道重塑,其机制可能通过促进TGF-β1表达而实现。     

阿奇霉素对哮喘致敏大鼠气道炎症及Th1/Th2失衡的调节作用

目的:探讨阿奇霉素对哮喘(OVA)致敏大鼠气道炎症及Th1/Th2失衡的调节作用。方法:SD大鼠40只,随机分为生理盐水组、哮喘模型组、地塞米松组以及阿奇霉素组,每组10只。利用卵白蛋白(Ovalbumin,OVA)/Al(OH)3致敏与OVA雾化吸入激发建立大鼠过敏性气道炎症模型,收集肺泡灌洗液(BALF)进行白细胞分类计数。采用ELISA法测定肺泡灌洗液中IL-2、IL-4、TNF-α与ET-1的表达情况。光镜观察肺组织病理结构变化。结果:OVA模型大鼠肺泡灌洗液中的中性粒细胞、淋巴细胞以及嗜酸性粒细胞含量明显增加;HE染色观察肺组织病理结构出现明显的支气管上皮脱落、杯状细胞增生,支气管周围嗜酸性粒细胞明显浸润现象;BALF中IL-2、IL-4、TNF-α与ET-1的表达均明显高于生理盐水对照组(P<0.05)。阿奇霉素则显著降低肺泡灌洗液中中性粒细胞、淋巴细胞以及嗜酸性粒细胞含量;明显改善支气管上皮脱落、杯状细胞增生,支气管周围嗜酸性粒细胞浸润现象;BALF中IL-2、IL-4、TNF-α与ET-1的表达也明显低于OVA模型大鼠(P<0.05)。结论:阿奇霉素通过调节Th1/Th2失衡对过敏性哮喘的气道炎症具有明显的治疗作用。     

虫草多糖对OVA过敏性哮喘鼠气道炎症和气道高反应的影响

目的 观察虫草多糖是否具有抗过敏性哮喘的作用。方法 建立小鼠哮喘模型,第0,14天,分别腹腔注射OVA及其佐剂,自21 d时开始雾化吸入OVA一次,连续14 d,吸入OVA前0.5 h,观察组予虫草多糖100 mg·kg^-1灌胃,阳性药物腹腔注射地塞米松。最后一次OVA雾化吸入后12 h进行气道高反应实验,之后收集支气管灌洗液进行细胞计数、分类、ELISA和RT-PCR检测,取左下肺组织做病理及免疫组化,观察肺组织炎症改变。结果 ①哮喘组气道反应性较正常组显著增高,虫草多糖治疗组气道反应性显著降低（P〈0.05）。②病理组织分析哮喘组支气管和小血管周围显示明显的嗜酸性粒细胞浸润,支气管黏液分泌增加;虫草多糖治疗组支气管和小血管嗜酸性粒细胞浸润程度明显减轻,支气管黏液分泌减少。③哮喘组BALF中出现大量嗜酸性粒细胞,虫草多糖治疗组较哮喘组嗜酸性粒细胞明显减少（P〈0.05）。④哮喘组支气管灌洗液中IL-4、IL-5、IL-13较正常组显著增加,虫草多糖治疗组较哮喘组明显降低（P〈0.05）。⑤哮喘组肺组织中IL-4、IL-5、IL-13 mRNA表达增加,虫草多糖治疗组较哮喘组表达降低。结论 虫草多糖治疗可在一定程度上减轻哮喘小鼠的气道嗜酸性粒细胞炎症及粘痰蛋白的分泌。     

咪喹莫特对哮喘小鼠气道炎症和调节性T细胞的影响

目的:观察咪喹莫特对小鼠哮喘模型气道炎症和调节性T细胞Foxp3表达的影响。方法:建立哮喘模型,第0、7、14天分别腹腔注射卵白蛋白(OVA)及其佐剂,自21 d时开始雾化吸入OVA一次,连续7 d,吸入OVA前0.5 h,咪喹莫特组雾化吸入咪喹莫特30 min(1.5 g/L),地塞米松组腹腔注射地塞米松(4 mg/kg)。最后一次OVA雾化吸入后48 h取左下肺组织做HE染色观察肺组织炎症改变;收集支气管肺泡灌洗液(BALF)进行细胞计数、分类和ELISA检测。结果:(1)HE染色显示咪喹莫特组小鼠肺组织炎症程度较哮喘小鼠轻。(2)哮喘组小鼠BALF中嗜酸性粒细胞较正常组显著增加(P<0.01),咪喹莫特组嗜酸性粒细胞比哮喘组显著减少(P<0.01)。(3)哮喘组BALF中IL-5水平较正常组显著升高(P<0.01),咪喹莫特治疗组比哮喘组显著降低(P<0.01)。哮喘组BALF中IL-10水平较正常组显著降低(P<0.01),咪喹莫特治疗组比哮喘组显著升高(P<0.05)。(4)哮喘组脾脏组织Foxp3+细胞数量较正常组减少,咪喹莫特组与地塞米松组较哮喘组增加(P<0.01)。结论:雾化吸入咪喹莫特可在一定程度上增加Foxp3+细胞数量,减轻哮喘小鼠的气道炎症。     

STAT6在哮喘小鼠肺组织的表达及激素的影响作用

目的探讨信号转导和转录激活因子(STAT)-6在支气管哮喘发病机制中的作用及激素的影响作用。方法经腹腔注射与鼻腔滴注卵白蛋白(OVA)制作小鼠哮喘模型,并设对照组和地塞米松干预组,激发后观察各组肺组织病理学改变,采用反转录-聚合酶链反应(RT-PCR)和免疫组织化学检测肺组织STAT6mRNA和蛋白表达。结果OVA末次激发24h后,病理组织学显示哮喘组小鼠肺组织可见大量炎细胞浸润,STAT6mRNA(2.46±0.24与1.41±0.26,P<0.01)及蛋白表达水平较对照组明显增加,地塞米松治疗后,小鼠肺组织炎细胞浸润减轻,STAT6mRNA(1.80±0.36与2.46±0.24,P<0.01)及蛋白表达水平下降。结论哮喘气道中STAT6过度表达,地塞米松可通过调控STAT6表达发挥抗炎作用。     

骨形态构建蛋白 2型受体下调单核细胞趋化蛋白 1/CC类趋化因子受体 2通路对哮喘小鼠气道炎症和 Th1/Th2平衡的影响

目的探究骨形态构建蛋白 2型受体( BMPR2)对小鼠哮喘模型气道炎症和 Th1/Th2平衡的影响及其机制。方法2021年 9月至 2022年 11月选用 24只 C57BL/6小鼠尾静脉注射 BMPR2腺病毒,随后卵清蛋白( OVA)致敏和激发建立哮喘小鼠于模型;采用随机数字表法分为对照组(生理盐水替代 OVA造模)、 OVA模型组( OVA诱导小鼠哮喘模型)、 OVA+载体( Vector)组(空载慢病毒处理的 OVA哮喘模型小鼠)OVA+BMPR2组( BMPR2过表达慢病毒处理的 OVA哮喘模型小鼠),每组 6只。收集支气管肺泡灌洗液( BALF)和肺组织。免疫、组织化学检测肺组织 BMPR2表达水平;苏木精 -伊红染色观察肺组织病理学改变;瑞氏染色后计数 BALF中各类炎症细胞数目;酶联免疫吸附测定( ELISA)试剂盒检测 BALF中白细胞介素( IL)-4,IL-5和 IL-13炎症因子水平;蛋白质印迹法检测肺组织和气道上皮细胞 16HBE中 BMPR2、单核细胞趋化蛋白 -1(MCP1)及其受体 CC类趋化因子受体 2(CCR2)蛋白表达水平。免疫共沉淀实验检测 BMPR2与 MCP1相互作用。结果与对照组相比, OVA模型组肺组织 BMPR2(0.36±0.05比 1.04±0.04)显著降低(P<0.01);小鼠肺泡破坏程度严重,肺组织有大量的淋巴细胞浸润; BALF中炎症细胞总数［(93.25±9.32)×104个/毫升比( 4.79±0.41)×104个/毫升, P<0.001］、嗜酸性粒细胞、中性粒细胞和淋巴细胞均升高; Th1相关炎症因子 γ干扰素( IFN-γ)水平降低, Th2相关炎症因子 IL-4,IL-5和 IL-13水平升高。过表达 BMPR2可降低肺泡破坏程度和淋巴细胞浸润程度。与 OVA+Vector组相比, OVA+BMPR2组 BALF中炎症细胞总数、嗜酸性粒细胞、中性粒细胞和淋巴细胞均降低; ELISA结果表明, OVA+BMPR2组 BALF中 IFN-γ水平升高, IL-4,IL-5和 IL-13水平降低,提示过表达 BMPR2可上调 Th1百分比,下调 Th2细胞百分比。进一步研究表明, BMPR2过表达显著下调了 MCP1及其受体 CCR2的表达水平,且 BMPR2与MCP1存在相互作用。结论 BMPR2可通过下调 MCP1/CCR2通路降低哮喘小鼠气道炎症,并调节 Th1/Th2平衡。     

热毒宁对呼吸道合胞病毒感染哮喘模型小鼠的影响

目的：探讨热毒宁（RDN）对呼吸道合胞病毒（RSV）感染哮喘加重小鼠气道炎症的影响。方法：雌性BALB/c小鼠32只,随机分成4组,分别为对照组、鸡卵白蛋白（OVA）组、OVA/RSV组、OVA/RSV/RDN组。无创肺功能检测各组小鼠气道反应性;HE染色观察肺部炎症变化;小鼠支气管肺泡灌洗液（BALF）中炎性细胞计数并分类;ELISA法检测BALF中IL-4、IL-5、IL-13、IFN-γ含量。结果：RSV感染能够加重哮喘小鼠气道炎症与气道高反应性, RDN抑制RSV感染哮喘加重小鼠气道高反应性（P〈0.05）;RDN显著减少RSV感染哮喘小鼠BALF 中IL-4、IL-5、IL-13、IFN-γ含量。结论：RDN可以减轻RSV感染的小鼠气道炎症反应,抑制气道高反应性。     

桂芍子喘颗粒对卵蛋白所致支气管哮喘小鼠的药效学研究

摘要：目的:研究桂芍子喘颗粒对卵蛋白（OVA）所致支气管哮喘小鼠药效学的影响。方法:84只SPF级BALB/c小鼠随机分为7组:正常对照组、模型组、桂芍子喘颗粒低(0.93 g·kg-1)、中(1.86 g·kg-1)、高(3.72 g·kg-1)剂量组、醋酸地塞米松组(0.63 mg·kg-1)、六君子丸+玉屏风颗粒组(2.5 g·kg-1+2.1 g·kg-1),每组12只。除正常对照组外,其余各组小鼠采用OVA建立支气管哮喘模型。建模第22天各组灌胃给药,正常对照组和模型组给予等量蒸馏水,1次/d,连续给药7 d,同时给予OVA溶液雾化刺激。第28天雾化刺激后,采用肺功能仪检测气道反应性; ELISA法检测血清免疫球蛋白E（IgE）、肺组织白细胞介素-4（IL-4）、白细胞介素-5（IL-5）、白细胞介素-17（IL-17）、肿瘤坏死因子-α（TNF-α）及嗜酸性粒细胞阳离子蛋白（ECP）水平;并进行肺泡灌洗液（BALF）中白细胞（WBC）和嗜酸性粒细胞（EOS）计数及肺组织病理学观察。结果:与正常对照组相比,模型组气道阻力升高,顺应性降低,IgE、IL-4、IL-17、TNF-α、ECP水平升高,病理损害明显,病理评分升高（P<0.05或P<0.01）。桂芍子喘颗粒可降低OVA所致支气管哮喘小鼠的气道阻力,提高气道顺应性;降低IgE、IL-4、IL-5、IL-17、TNF-α、ECP水平;减少肺泡灌洗液WBC和EOS的数量,减轻肺组织病理损伤（P<0.05或P<0.01）。结论:桂芍子喘颗粒对OVA所致支气管哮喘小鼠气道反应性、炎症反应及肺组织病理学损害具有改善作用。     

黄芪多糖对哮喘大鼠Th17/Treg细胞因子及肺部炎症的影响

目的 观察黄芪多糖(astragalus polysaccharide,APS)对哮喘大鼠支气管肺泡灌洗液(bronchoalveolar lavage fluid,BALF))中IL-17A、IL-25、IL-35、IL-10水平及肺部炎症的影响,探讨其对哮喘的治疗作用及其机制.方法 实验分为正常组、模型组、黄芪多糖组.通过OVA腹腔注射致敏及OVA雾化吸入激发制备哮喘大鼠模型.采用肺组织HE染色评价大鼠肺部炎症;瑞氏染色检测BALF中炎症细胞总数及分类;电镜观察Ⅱ型肺泡上皮细胞超微结构的变化;酶联免疫技术检测BALF中Th17细胞因子IL-17A、IL-25以及Treg细胞因子IL-35、IL-10的水平.结果 哮喘组大鼠肺组织炎症表现显著,Ⅱ型肺泡上皮超微结构损伤明显,BALF中IL-17A、IL-25含量明显升高(P<0.05),而IL-35、IL-10含量明显降低(P<0.05).APS干预降低可BALF中炎症细胞总数、淋巴细胞、嗜酸性粒细胞以及巨噬细胞数量(P<0.05),降低BALF中IL-17A、IL-25含量(P<0.05),升高IL-35、IL-10含量(P<0.05).结论 黄芪多糖治疗哮喘的机制可能与调节哮喘机体Th17/Treg细胞因子间的平衡有关.     

Administration of mycobacterial Ag85A and IL-17A fusion protein attenuates airway inflammation in a murine model of asthma

Interleukin (IL)-17A contributes to the development of asthma, especially in severe asthma which has characteristic neutrophil infiltration in airways. However, IL-17A-blocking antibody could escalate T helper (Th) 2 cytokines, such as IL-13, IL-4 in murine models. We aimed at determining the effect of mycobacterial Ag85A and IL-17A fusion protein—Ag85A-IL-17A on airway inflammation in a murine model of asthma. IL-17A recombinant protein fused mycobacterial immunodominant antigen Ag85A was constructed, expressed and purified. The fusion protein was then administrated into BALB/c mice and its anti-inflammatory effects in the infiltration of inflammatory cells, Th2/Th17 cytokines in BALF, histopathological changes of lung tissues as well as chemokines in lung tissues were evaluated in the murine model of asthma. We found that administration of mycobacterial Ag85A and IL-17A fusion protein induced IL-17A specific immunoglobulin (Ig)G in sera and significantly decreased IL-17A and IL-6 levels in bronchoalveolar lavage fluid (BALF). Ag85A-IL-17A vaccinated mice also showed marked reduction in the infiltration of inflammatory cells in peribronchiolar region and significant decrease in total cells, eosinophil cells and neutrophil cells in BALF. The increased levels of IL-13 and IL-4 in BALF of ovalbumin-sensitized mice were significantly reduced by the administration of Ag85A-IL-17A. Furthermore, CD3⁺CD4⁺IL-13⁺ splenocytes stimulated with OVA and CXCL1 mRNA, CCL2 mRNA and GATA-3 mRNA expressed in lung tissues were decreased markedly in Ag85A-IL-17A vaccinated group. Our results demonstrate remarkable antiallergic effects of Ag85A-IL-17A in a murine model of asthma and it may have protective effects on allergic asthma.     

Dexamethasone alleviate allergic airway inflammation in mice by inhibiting the activation of NLRP3 inflammasome

Dexamethasone (DEX) is the mainstay treatment for asthma, which is a common chronic airway inflammation disease. However, the mechanism of DEX resolute symptoms of asthma is not completely clear. Here, we aimed to analyze the effect of DEX on airway inflammation in OVA-induced mice and whether this effect is related to the inhibition of the activation of NLRP3 inflammasome. Female (C57BL/6) mice were used to establish the allergic airway inflammation model by inhalation OVA. The number of inflammatory cells in the bronchi alveolar lavage fluid (BALF) was counted by Swiss-Giemsa staining, and the contents of IL-1β, IL-18, IL-5 and IL-17 were detected by ELISA. The degree of inflammatory cells infiltration and mucous cells proliferation in lung tissue were separately observed by H&E and PAS staining. The proteins expression of NLRP3, pro-caspase-1, caspase-1, IL-1β, IL-6 and IL-17 in lung tissue were detected by Western blotting. We found that DEX significantly inhibited OVA-induced inflammatory cells infiltration, airway mucus secretion and goblet cell proliferation in mice. The total and classified numbers of inflammatory cells and the levels of IL-1β, IL-18, IL-5 and IL-17 in the BALF of the experimental group were significantly lower than those of the model group after DEX treatment. DEX also significantly inhibited the activity of NLRP3 inflammasome and reduced the protein contents of Pro-Caspase-1, Caspase-1, Capase-1/Pro-Caspase-1, IL-1β, IL-6 and IL-17 in lung tissues. Our study suggested that DEX alleviates allergic airway inflammation by inhibiting the activity of NLRP3 inflammasome and the levels of IL-1β and IL-18.     

The effects of chrysophanol on ovalbumin (OVA)-induced chronic lung toxicology by inhibiting Th17 response

Chrysophanol (CH), extracted from plants of Rheum genus, possesses various pharmacological effects including anti-inflammatory activity. The purpose of the present study was to evaluate the protective effects and the underlying mechanisms of CH on ovalbumin (OVA)-induced asthma in mice. Fifty mice were randomly assigned to five experimental groups: control group, model group, dexamethasone (2?mg/kg) group and CH (5 and 10?mg/kg) groups. The number of eosinophil cells and the production of interleukin-6 (IL-6), IL-1β, IL-17?A and tumor necrosis factor-α in bronchoalveolar lavage fluid (BALF) were measured. In addition, pulmonary histopathology, airway resistance (Raw), T-helper17 (Th17) cells frequency and RORγt expression were evaluated. Our study demonstrated that CH effectively decreased eosinophil count and inflammatory cytokines production in BALF. In addition, treatment with CH significantly inhibited the Raw, Th17 percentage and RORγt expression in OVA-induced animals compared with those in model group. Histological studies also demonstrated that CH significantly suppressed OVA-induced eosinophilia in lung tissue compared with model group. Our findings supported that CH can prevent allergic asthma in the mouse model.     

磷酸酰肌醇-3激酶抑制剂对小鼠气道炎症影响的实验研究

目的观察磷酸酰肌醇-3激酶（P13K）抑制剂LY294002对卵白蛋白诱导哮喘小鼠气道炎症的影响。方法Balb／c小鼠30只，采用随机数字表法分为3组，每组10只：LY294002处理组、卵白蛋白组、正常对照组。通过卵白蛋白多次腹腔注射致敏和反复雾化激发，建立哮喘小鼠模型。末次抗原激发后48h收集支气管肺泡灌洗液和骨髓标本，计数细胞总数和嗜酸性粒细胞，并行肺组织学检查。结果与卵白蛋白组比较，LY294002处理组支气管肺泡灌洗液中细胞总数及嗜酸性粒细胞绝对数明显减少（P〈0．05）：肺组织中细支气管、血管周围嗜酸性粒细胞浸润得到控制，气道黏液分泌减少。结论P13K特异性抑制剂LY294002对卵白蛋白致敏的哮喘小鼠气道炎症具有抑制作用。     

Effect of Syringic acid on antioxidant biomarkers and associated inflammatory markers in mice model of asthma

Asthma is termed as the induction of chronic inflammation in the airway lumen of lungs due to accumulation of inflammatory cells which affects normal breathing process. Prolonged accumulation of inflammatory cells leads to oxidative stress and suppression of antioxidant activities. Therefore, in our present investigation, a potential phenolic compound, Syringic acid was tested for the suppression of inflammatory markers toward an antiasthmatic activity in ovalbumin (OVA)-induced asthmatic mice model. As a result, the Syringic acid treatment was found to suppress the inflammatory cells; eosinophil, neutrophil, macrophage, lymphocyte, and other inflammatory markers including IL-4, IL-5, IL-13, and TNF-α in the BALF of OVA-induced asthmatic mice. Similarly, IgE levels were significantly reduced in the blood serum of Syringic acid treated mice groups. In this context, the IFN-γ levels were found enhanced in the BALF of Syringic acid treated asthmatic mice groups, expressing an anti-inflammatory response. Enzymatic and nonenzymatic antioxidants such as SOD, CAT, and GSH levels were found high in the Syringic acid treatment than the asthmatic control group, which depicts the antioxidant response of Syringic acid on asthmatic groups. Intriguingly, the ROS, NO₂, NO₃, and MDA levels were inhibited in the BALF of Syringic acid treated mice groups. The airway hyper-reactivity (AHR) was comparatively normal in the Syringic acid treatment as it was severe in the case of asthmatic control group. Consequently, the effect of Syringic acid is prominent in the treatment of asthma by controlling the accumulation of inflammatory cells, other inflammatory markers along with enhancement of antioxidant markers, suppression of ROS and controlling airway hyperreactivity. Hence, Syringic acid may be recommended for clinical trials in the treatment of asthma.     

胸腺肽β_4对哮喘小鼠气道炎症的作用

目的观察胸腺肽β_4对哮喘小鼠气道炎症的影响。方法 60只健康C57BL/6小鼠,随机分为正常对照组,哮喘模型组,地塞米松(25 mg·kg~(-1))组,胸腺肽β_4高剂量(5 mg·kg~(-1))组、中剂量(2.5 mg·kg~(-1))组和低剂量(1.25 mg·kg~(-1))组,每组10只。用卵白蛋白致敏法建立小鼠哮喘模型。正常对照组及哮喘模型组腹腔注射生理盐水,其他组注射相应药物,每日1次,共7 d。Medlab生理信号采集系统测定各组小鼠的肺功能,收集小鼠支气管肺泡灌洗液(BALF)进行细胞分类计数并检测小鼠血清中白细胞介素5(IL-5)的含量。结果哮喘模型组呼吸频率高于正常对照组,潮气量和肺每分钟通气量低于正常对照组,血清中IL-5浓度和BALF中嗜酸粒细胞百分比高于正常对照组(P<0.05)。胸腺肽β_4高剂量组和地塞米松组潮气量和肺每分钟通气量高于哮喘模型组,血清IL-5浓度低于哮喘模型组(P<0.05)。胸腺肽β_4各剂量组和地塞米松组呼吸频率均低于哮喘模型组,BALF中嗜酸粒细胞百分比也均低于哮喘模型组(P<0.05)。结论胸腺肽β_4能抑制哮喘小鼠嗜酸粒细胞、调节IL-5的水平,改善小鼠的肺通气功能。     

三叶青藤正丁醇部位对DBA/1小鼠胶原性关节炎的作用及机制

目的：观察三叶青藤正丁醇部位（nbuIR）对胶原性关节炎小鼠关节病变及血清炎症因子的抑制作用。方法：用DBA/1小鼠建立胶原性关节炎（CIA）动物模型,将造模成功小鼠随机分为模型对照组、甲氨蝶呤组、nbuIR低、中、高剂量组,另设正常对照组。灌胃给药,给药期间每周进行一次关节炎指数评分。干预结束后,ELISA法检测各组小鼠血清IL-23和IL-17水平,H-E染色观察各组小鼠踝关节组织病理学改变。结果：与模型对照组比较,nbuIR高剂量组血清IL-23和IL-17水平明显降低（P<0.01）,滑膜细胞增生与炎症细胞浸润程度明显减轻。结论：nbuIR能改善CIA小鼠局部关节肿胀,下调血清IL-23和IL-17水平,减少滑膜炎症程度,其机制可能与调节IL-23/IL-17轴有关。     

Copaiba oil suppresses inflammation in asthmatic lungs of BALB/c mice induced with ovalbumin

Asthma is a chronic inflammatory disease that represents high hospitalizations and deaths in world. Copaiba oil (CO) is popularly used for relieving asthma symptoms and has already been shown to be effective in many inflammation models. This study aimed to investigate the immunomodulatory relationship of CO in ovalbumin (OVA)-induced allergic asthma. The composition of CO sample analyzed by GC and GC–MS and the toxicity test was performed in mice at doses of 50 or 100 mg/kg (by gavage). After, the experimental model of allergic asthma was induced with OVA and mice were orally treated with CO in two pre-established doses. The inflammatory infiltrate was evaluated in bronchoalveolar lavage fluid (BALF), while cytokines (IL-4, IL-5, IL-17, IFN-γ, TNF-α), IgE antibody and nitric oxide (NO) production was evaluated in BALF and lung homogenate (LH) of mice, together with the histology and histomorphometry of the lung tissue. CO significantly attenuated the number of inflammatory cells in BALF, suppressing NO production and reducing the response mediated by TH2 and TH17 (T helper) cells in both BALF and LH. Histopathological and histomorphometric analysis confirmed that CO significantly reduced the numbers of inflammatory infiltrate in the lung tissue, including in the parenchyma area. Our results indicate that CO has an effective in vivo antiasthmatic effect.     

Therapeutic effects of anti-B7-1 antibody in an ovalbumin-induced mouse asthma model

Allergic asthma is a chronic inflammatory disorder of airways, which is characterized by attacks provoked by exposure to so-called asthma triggers, such as pet dander, second-hand tobacco smoke, dust mites, and mold spores. B7-1 (CD80), perhaps one of the most studied co-stimulatory molecules involved in asthma, plays a key role in regulating allergen-induced T cell activation in asthma, probably through T cell recruitment and Th cell differentiation upon allergen provocation. The present study was designed to test the hypothesis that anti-B7-1 antibody has therapeutic effects in asthma by blocking B7-1/CD28 pathway. The asthma model was established by ovalbumin (OVA) sensitization and challenging in female Balb/c mice. One hour after the last induction, mice were sacrificed and whole lung lavage was conducted. Cell numbers in bronchoalveolar lavage fluid (BALF) were determined and the expression levels of IFN-gamma and IL-4 in supernatant were measured by an enzyme-linked immunosorbent assay method. Sedimental cells smears were stained with Wright's-Gimsa mixed coloring method. The B7-1 expression was detected by immunohistochemistry method with frozen tissue sections. The anti-B7-1 antibody treatment could alleviate asthmatic syndromes induced by OVA. The number of recoverable eosinophils in BALF in the anti-B7-1 antibody treated group was significantly lower than that in the control group (P<0.01) and the eosinophils peribronchial infiltration was remarkably reduced in anti-B7-1 treated asthmatic mice, based on histological evaluation. The treatment with the anti-B7-1 antibody induced IFN-gamma expression and decreased IL-4 expression, compared with the asthmatic control group (P<0.01). In conclusion, the anti-B7-1 antibody approach may provide a novel therapy for allergic asthma.     

射干麻黄药对对支气管哮喘小鼠模型气道炎症及外周血Th1/Th2的影响

目的:观察不同比例射干麻黄药对对支气管哮喘小鼠模型气道中炎症细胞及外周血Th1/Th2平衡的影响.方法:将80只BALB/c小鼠随机分为A正常对照组、B哮喘模型组、C地塞米松组、D麻黄单药组、E射干单药组及不同比例射干麻黄药对组F、G、H),每组10只.采用鸡卵蛋白(OVA)致敏和激发建立小鼠哮喘模型,给予不同药物对小鼠进行干预.干预完成后取支气管肺泡灌洗液(BALF)测定白细胞总数及嗜酸性粒细胞计数,采用ELISA检测小鼠血清中IL-4、IL-5、IL-13及IFNγ的水平,HE染色观察小鼠肺组织病理炎症等改变.结果:射干麻黄药对组可以显著减轻哮喘小鼠的哮喘症状,降低外周血中IL-4、IL-5、IL-13水平、升高IFN-γ水平,并能降低BALF中白细胞总数及嗜酸粒细胞水平.结论:射干麻黄药对可以显著减轻哮喘小鼠气道炎症,抑制炎症介质的释放,纠正Th1/Th2失衡,从而达到治疗哮喘的作用.